These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30293232)

  • 21. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.
    Lin NU; Seah DS; Gelman R; Desantis S; Mayer EL; Isakoff S; Dipiro P; Krop IE; Come SE; Weckstein D; Winer EP; Burstein HJ
    Breast Cancer Res Treat; 2013 Jun; 139(2):403-10. PubMed ID: 23645007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
    Gori S; Colozza M; Mosconi AM; Franceschi E; Basurto C; Cherubini R; Sidoni A; Rulli A; Bisacci C; De Angelis V; Crinò L; Tonato M
    Br J Cancer; 2004 Jan; 90(1):36-40. PubMed ID: 14710203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
    Burstein HJ; Kuter I; Campos SM; Gelman RS; Tribou L; Parker LM; Manola J; Younger J; Matulonis U; Bunnell CA; Partridge AH; Richardson PG; Clarke K; Shulman LN; Winer EP
    J Clin Oncol; 2001 May; 19(10):2722-30. PubMed ID: 11352965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.
    Krajnak S; Decker T; Schollenberger L; Rosé C; Ruckes C; Fehm T; Thomssen C; Harbeck N; Schmidt M
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3391-3400. PubMed ID: 33743073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
    Xu B; Hu X; Zheng H; Wang X; Zhang Q; Cui S; Liu D; Liao N; Luo R; Sun Q; Yu S
    Oncotarget; 2016 Aug; 7(31):50643-50655. PubMed ID: 27276706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
    Lin PC; Wang WS; Yang MH; Yen CC; Chao TC; Hsiao LT; Chen PM
    J Chin Med Assoc; 2006 Jul; 69(7):304-9. PubMed ID: 16903643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.
    Stuart NS; McIllmurray MB; Bishop JL; Johnston SR; Price CG; O'Reilly SM; Joffe JK; Neave F; Whipp EC
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):152-6. PubMed ID: 18083354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.
    Heinemann V; Di Gioia D; Vehling-Kaiser U; Harich HD; Heinrich B; Welt A; Ziske C; Deutsch G; Pihusch R; Kölbl H; Hegewisch-Becker S; Michl M; Stemmler HJ
    Ann Oncol; 2011 Mar; 22(3):603-608. PubMed ID: 20724574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
    Macpherson IR; Spiliopoulou P; Rafii S; Saggese M; Baird RD; Garcia-Corbacho J; Italiano A; Bonneterre J; Campone M; Cresti N; Posner J; Takeda Y; Arimura A; Spicer J
    Breast Cancer Res; 2019 Dec; 22(1):1. PubMed ID: 31892325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer.
    Seo HY; Lee HJ; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Lee ES; Kim YH; Kim JS; Seo JH
    Invest New Drugs; 2011 Apr; 29(2):360-5. PubMed ID: 19943080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study.
    Hassan M; Osman MM
    Hematol Oncol Stem Cell Ther; 2010; 3(4):185-90. PubMed ID: 21150238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience.
    Di Lauro V; Murrone A; Bidoli E; Magri MD; Crivellari D; Veronesi A
    Tumori; 2008; 94(4):464-8. PubMed ID: 18822679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
    Ahn JH; Kim SB; Kim TW; Ahn SH; Kim SM; Park JM; Lee JS; Kang YK; Kim WK
    J Korean Med Sci; 2004 Aug; 19(4):547-53. PubMed ID: 15308846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
    Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
    Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.